John Maraganore

This article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) The neutrality of this article is disputed. Relevant discussion may be found on the talk page. Please do not remove this message until conditions to do so are met. (December 2021) (Learn how and when to remove this template message) The topic of this article may not meet Wikipedia's notability guideline for biographies. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources:  –  ·  ·  · scholar · JSTOR (December 2021) (Learn how and when to remove this template message) This article's tone or style may not reflect the encyclopedic tone used on Wikipedia. See Wikipedia's guide to writing better articles for suggestions. (October 2021) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

John Maraganore is an American scientist and life sciences industry leader.^[1][2][3][4]

Education[]

John was born in Chicago, Illinois, U.S. in 1962 to Greek immigrant parents. In 1984, he completed his B.A. from University of Chicago in Division of Biological Sciences. In1985, he completed his M.S. from the University of Chicago in Department of Biochemistry and Molecular Biology. In 1986, Maraganore received his Ph.D. from the University of Chicago in Department of Biochemistry and Molecular Biology.^[5][6]

Career[]

Maraganore started his career as a post-doctoral research scientist at Upjohn in Kalamazoo, Michigan, from 1985-86. From 1986-87, he was a senior scientist at Zymogenetics in Seattle, Washington. From 1987-1997, he was a senior scientist, group leader of thrombosis and hemostasis research, director of biological research, director of market and business development, and program executive at Biogen in Cambridge, Massachusetts. At Biogen, he invented bivalirudin, a direct-acting thrombin inhibitor, later commercialized in the U.S. as ANGIOMAXTM. In 1997, Maraganore joined Millennium Pharmaceuticals and was the general manager of their Biotherapeutics subsidiary till 1999. He then became vice-president of mergers, acquisitions, and strategic planning and led the acquisitions of Leukosite and Cor Therapeutics. In 2000, he was appointed senior vice-president of strategic product development.^[7][8][9]

Since 2002, John has been serving as the founding chief executive officer and a member of the Board of Directors at Alnylam Pharmaceuticals. At Alnylam, he led the company’s pioneering efforts to advance RNA interference therapeutics and formed over 25 major partnerships with leading pharmaceutical and biotechnology companies, and raised over $7 billion to fund the company’s research, development, manufacturing, and commercialization activities. Maraganore was the chairman of the Biotechnology Innovation Organization also known as BIO from 2017-2019 and serves as a member of the BIO board and its executive committee. He is also a director of Agios Pharmaceuticals and of the Termeer Foundation, which advances the legacy of the late Henri Termeer. He is an active mentor to emerging leaders across the biotechnology industry and also serves in advisory roles for General Atlantic, Pictet, and Brii Biosciences.^{[10][11][12][13][14][15]}

References[]